Curemeta LLC, a Boston-based oncology biotech, will be at the IBC Life Science Conference in San Francisco. They will be presenting data on their ADCs which target pluripotent cancer stem cells.
Curemeta LLC to Present at IBC Life Science 2015 San Francisco, CA, May 16, 2015 –(PR.com)– Curemeta LLC announces they will be attending the IBC Life Science Conference (Bioconjugates; from targets to therapeutics) at Parc 55, Hilton from May 18-20. They will be presenting their poster “ADCs Targeting Pluripotent Stem Cells” (poster #9).
CureMeta is a Boston-based biotech bringing a unique approach to oncology research by developing new and powerful drugs to target metastatic cancers. Based on ideas and concepts linking cell pluripotency with metastatic and aggressive cancers, CureMeta is building a platform of potential cancer drug therapies through targeted antibody drug conjugates.